Analgesic compositions containing buprenorphine
View Patent ↗An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or an amount of naltrexone or nalmefene such that the ratio by weight of buprenorphine to naltrexone or nalmefene is in the range of from 12.5:1 to 22.5:1. The analgesic action of the buprenorphine is potentiated by the low dose of naloxone, naltrexone or nalmefene.
1. A method for the treatment of pain in a human or animal subject, which method comprises administering to the human or animal, by the parenteral route or via the mucosa, of from 1.25 μg to 10 μg per kilogram of body weight of buprenorphine per day and
an amount of naloxone such that the ratio by weight of buprenorphine to naloxone administered is in the range of from 12.5:1 to 27.5:1.
2. A method as claimed in claim 1 which comprises administering buprenorphine in a unit dosage in combination with naloxone.
3. A method as claimed in claim 2 wherein the ratio by weight of buprenorphine to naloxone administered to the human or animal is in the range of from 15:1 to 20:1.
4. A method as claimed in claim 2 wherein the amount of buprenorphine administered to the human or animal is from 1.25 μg to 5 μg per kilogram of body weight.
5. A method as claimed in claim 4 wherein the ratio by weight of buprenorphine to naloxone administered to the human or animal is in the range of from 15:1 to 20:1.
6. A method according to claim 2 in which the buprenorphine in combination with naloxone is administered in sublingual form.